Advertisement

Labelling Micro-Organisms and Parts of Micro-Organisms

  • V. Cardoso
  • F. J. H. N. Braga
Part of the Developments in Nuclear Medicine book series (DNUM, volume 34)

Abstract

Nuclear medicine techniques are widely used to image foci of infection and inflammation. Among the relatively new radiopharmaceuticals aimed for this purpose are the radioimmunoconjugates, such as labelled murine monoclonal antigranulocyte antibodies and labelled human polyclonal nonspecific immunoglobulin G. Rapid and accurate localisation of infectious and inflammatory lesions have substantial therapeutic impact in many clinical conditions. Radioimmunoconjugates can contribute to both diagnosis elucidation and to implement a tailored therapeutic strategy.

Keywords

Infective Endocarditis Unknown Origin Invasive Aspergillosis Invasive Pulmonary Aspergillosis National Nosocomial Infection Surveillance System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Woods G, Gutierrez Y, Walker D, Purtilo D, Shanley J. 1993; Diagnostic pathology of infectious diseases. Philadelphia: Lea & Febiger.Google Scholar
  2. 2.
    Goldenberg DM, Sharkey RM, Udem S, Vagg R, Levine GM, Conte P, Swayne LC, Hansen HJ, Cunnif D, Anton J, Linke MJ, Smulian G, Walzer PD. Immunoscintigraphy of Pneumocytis carinii in AIDS patients. J Nucl Med 1994; 35: 1028–1034.PubMedGoogle Scholar
  3. 3.
    Becker W. The contribution of nuclear medicine to the patient with infection. Eur J Nucl Med 1995; 22: 1195–1211.PubMedGoogle Scholar
  4. 4.
    Hoffer P. Gallium: Mechanisms..1 Nuc1 Med 1980; 21: 282–285.Google Scholar
  5. 5.
    Petersdorf RG, Beeson PB. Fever of unknown origin: report of 100 cases. Medicine 1961; 40: 1–30.PubMedGoogle Scholar
  6. 6.
    Shoen RP, van Ommen RA. Fever of obscure origin. Am J Med 1963; 34: 486.Google Scholar
  7. 7.
    Frayha R, Uwaydah M. Fever of unknown origin. Lab Med J1973;26: 49.Google Scholar
  8. 8.
    Howard P Jr, Hahn HH, Palmer PL. Fever of unknown origin. A prospective study of 100 patients. Tex Med 1977; 73: 56.PubMedGoogle Scholar
  9. 9.
    Larson EB, Featherstone HJ, Petersdorf RG. Fever of undermined origin: diagnosis and follow-up in 105 patients - 1970–1980. Medicine 1982; 61: 269.PubMedGoogle Scholar
  10. 10.
    Knockaert DC, Vanneste U, Vanneste SB. Fever of unknown origin in the 1980s. An update of the diagnostic spectrum. Arch Intern Med 1992; 152: 51.PubMedGoogle Scholar
  11. 11.
    Palestro CJ, Kim CK, Swyer A.1, Vallabhajosula S, Goldsmith Si. Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and Tc-99m methylene diphosphonate bone scintigraphy. J Nucl Med 1991; 32: 1861–65.PubMedGoogle Scholar
  12. 12.
    Reuland P, Winkler KH, Heuchert T, Ruck P, Müller-Schauenburg W, Weller S, Feine U. Detection of infection in postoperative orthopedic patients with technetium-99m-labeled monoclonal antibodies against granulocytes. J Nucl Med 1991; 32: 526–31.Google Scholar
  13. 13.
    Hotze A, Briele B, Overbeck B, Knopp J, Grünwald F, Mekkawy MA, von Smekal A, Moeller F, Biersack HJ. Tc-99m-labelled antigranulocyte antibodies in suspected bone infections. J Nucl Med 1992; 33: 526–31.PubMedGoogle Scholar
  14. 14.
    Sciuk J, Brandau W, Vollet B, Stucker R, Erlemann R, Bartenstein R, Peters PE, Schober O. Comparison of Tc-99m polyclonal human immunoglobulin and Tc-99m-labeled monoclonal antibodies for imaging chronic osteomyelitis. Eur J Nucl Med 1991; 18: 401–7.PubMedGoogle Scholar
  15. 15.
    Palestro CJ. The current role of gallium imaging in infection. Semin Nucl Med 1994; XXIV: 128–41.Google Scholar
  16. 16.
    De Schrijver M, Streule K, Senekowitsch R, Fridrich R. Scintigraphy of inflammation with nanometer-sized colloid tracers. Nucl Med Commun 1987; 8: 895–908.PubMedGoogle Scholar
  17. 17.
    McAfee JG, Gagne G, Subramanian G, Schneider RF. The localization of indium-lllleukozytes, gallium-67, polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. J Nucl Med 1991; 32: 2126–31.PubMedGoogle Scholar
  18. 18.
    Wheeler JG, Slack NF, Duncan A, Palmer H, Harvey RF. Tc-99m-nanocolloid in inflammatory bowel disease. Nucl Med Commun 1990; 11: 127–33.PubMedGoogle Scholar
  19. 19.
    Streule K, de Schrijver M, Friedrich R. Tc-99m-labelled HSA-nanocolloid versus In-111 oxine labeled granulocytes in detecting skeletal septic process. Nucl Med Commun 1988; 9: 59–67.PubMedGoogle Scholar
  20. 20.
    van Dalen H, Stemfort AF, de Jonge-Bok JM, de Schrijver M. Three phase scintigraphy of Tc-99m nanocolloid versus Tc-99m M DP in orthopedics. In: Stuttgart: Schattauer 1989; 474–7.Google Scholar
  21. 21.
    Vorne M, Lantto S, Paakkinen S, Salo S, Soini I. Clinical comparison of Tc-99m HMPAO labeled leukocytes and Tc-99m-nanocolloid in the detection of inflammation. Acta Radiol 1989; 30: 633–7.PubMedGoogle Scholar
  22. 22.
    Hotze A, Bokisch A, Rüther M, Biersack HJ. Comparison of Tc-99m-HMPAO labelled leukocytes and Tc-99m nanocolloid in osteomyelitis. Nukl Med 1988; 27: 63–5.Google Scholar
  23. 23.
    Flivik G, Sloth M, Rydholf U, Herrlin K, Lidgren L. Technetium-99m-nanocolloid scintigraphy in orthopedic infections: a comparison with In-111-labeled leukocytes. J Nucl Med 1993; 34: 1646–50.PubMedGoogle Scholar
  24. 24.
    Liberatore M, Clemente M, lurilli AP, Zorzin L, Masini M, Di Rocco E, Centi Colella A. Scintigraphic evaluation of disease in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 1992; 19: 853–7.PubMedGoogle Scholar
  25. 25.
    McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Solube agents. J Nucl Med 1976; 17: 480–7.PubMedGoogle Scholar
  26. 26.
    McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. 11. Particles. J Nucl Med 1976; 17: 488–92.PubMedGoogle Scholar
  27. 27.
    Spector WG, Lykke WJ, Willoubhgy PA. A quantitative study of leukocyte emigration in chronic inflammatory granulomata. J Pathol Bacteriol 1967; 93: 101–7.PubMedGoogle Scholar
  28. 28.
    McAfee JG, Gagne GM, Subramanian G. Distribution of leukocytes labeled with In-11 I-oxine in dogs with acute inflammatory lesions. J Nucl Med 1980; 21: 1059–68.PubMedGoogle Scholar
  29. 29.
    Thakur ML, Lavender JP, Amot RN, Silvester DJ, Segal AW. Indium-111-labeled autologues leukocytes in man. J Nucl Med 1977; 18: 1012–21.Google Scholar
  30. 30.
    Becker W, Fischbach W, Reiners C, Börner W. Three-phase white blood cell scan: diagnostic validity in abdominal inflammatory diseases. J Nucl Med 1986; 27: 1109–15.PubMedGoogle Scholar
  31. 31.
    Saverymuttu SH, Peters AM, Chadwick VJ, Hodgson Hi, Lavender JP. Imaging diseased bowel with In-111 labelled white cells. Br J Radiol 1981; 54: 707.Google Scholar
  32. 32.
    Peters AM, Saverymuttu SH, Keshavarzian A, Bell RN, Lavender JP. Imaging of inflammation with In-111-tropolonate labeled leukocytes. J Nucl Med 1983; 24: 39–44.PubMedGoogle Scholar
  33. 33.
    Sinn H, Silvester DJ. Simplified cell labelling with In-111 acetylacetone. Br J Radiol 1979; 52: 758–9.PubMedGoogle Scholar
  34. 34.
    Datz FL. In-111-labeled leukocytes for the detection of infection: current status. Semin Nucl Med 1994; XXIV: 92–109.Google Scholar
  35. 35.
    Golden DW, Cline MJ. Production, distribution and fate of granulocytes. In: Williams WJ, Beutler E, Erslev Ai, et al., eds 1977; Hematology 2nd ed New York: McGraw Hill. 699–706.Google Scholar
  36. 36.
    Athens JW, Haab OP, Raab SO. Leukokinetic studies: the total blood, circulating and marginal granulocyte pools and granulocyte turnover rate in normal subjects. J Clin Invest 1961; 40: 989–95.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Weiblen BJ, Forstrom LA, McCullogh J. Kinetics of In-111-labelled granulocytes. J Lab Clin Med 1979; 94: 246–55.PubMedGoogle Scholar
  38. 38.
    Bassano DA, McAfee JG. Cellular radiation doses of labeled neutrophils and platelets. J Nucl Med 1979; 20: 255–9.PubMedGoogle Scholar
  39. 39.
    Thakur ML, McAfee JG. The significance of chromosomal aberrations in In-111-lymphocytes. J Nucl Med 1984; 25: 922–7.PubMedGoogle Scholar
  40. 40.
    Oswald SG, Norstrand DV, Savory CG, et al. Three phase bone scan and indium white blood cell scintigraphy following porous coated hip arthroplasty: a prospective study of the prosthetic hip. J Nucl Med 1989; 30: 1321–31.PubMedGoogle Scholar
  41. 41.
    Saverymuttu SH, Camillieri M, ReesHLavender JP, Hodgson HJF, Chadwick VS. Indium- 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology and fecal indium-111 granulocyte excretion. Gastroenterology 1986; 90: 1121–8.PubMedGoogle Scholar
  42. 42.
    Becker W, Fischbach H, Jenett M, Reiners C, Börner W. In-I I1-oxine labelled white cells in the diagnosis and follow-up of Crohn’s disease. Klein Wochenschr 1986; 64: 141–8.Google Scholar
  43. 43.
    Fischbach W, Becker W. Clinical relevance of activity parameters in Crohn’s disease estimated by fecal excretion of In-111-labeled granulocytes. Digestion 1991; 50: 149–52.PubMedGoogle Scholar
  44. 44.
    Becker W, Fischbach W, Weppler M, Mösl B, Jocoby G, Börner W. Radiolabeled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications. Nucl Med Commun 1988; 9: 693–701.PubMedGoogle Scholar
  45. 45.
    Saverymuttu SH, Crofton ME, Peters AM, Lavender JP. Indium-111 tropolonate leukocyte scanning in the detection of intra-abdominal abscesses. Clin Radiol 1983; 34: 593–6.PubMedGoogle Scholar
  46. 46.
    McCarthy K, Velchik MG, Alavi A, Mandell GA, Esterhai JL, Goll S. In-111-labelled white blood cells in the detection of osteomyelitis complicated by a pre-existing condition. J Nucl Med 1988; 29: 1015–21.PubMedGoogle Scholar
  47. 47.
    Pring DJ, Henderson RG, Keshavarzian A, Rivett AG, Krausz T, Coombs RRH, Lavender JP. Indium granulocyte scanning in painful prosthetic joint. Radiology 1991; 179: 645–7.Google Scholar
  48. 48.
    Palestro CJ, Kim DK, Swyer AJ, Vallabhajosula S, Goldsmith S. Radionuclide diagnosis of vertebral osteomyelitis: In-Ill-leukocyte and Tc-99m methylene diphosphonate bone scintigraphy. J Nucl Med 1991; 32: 1861–5.PubMedGoogle Scholar
  49. 49.
    Becker W, Düsel W, Berger P, Spiegel W. In-I11-granulocyte scan in prosthetic vascular graft infections: imaging technique and results. Eur J Nucl Med 1987; 13: 225–9.PubMedGoogle Scholar
  50. 50.
    Becker W, Borst U, Maisch B, Epping J, Börner W, Kochsiek K. In-111-labelled granulocytes in inflammatory hear diseases. Eur Heart J 1987; 8 Suppl J: 307–10.Google Scholar
  51. 51.
    Borst U, Becker W, Maisch B, Bömer W, Kochsiek K. Clinical and prognostic effect of a positive granulocyte scan in infective endocarditis. Clin Nucl Med 1993; 18: 35–9.PubMedGoogle Scholar
  52. 52.
    Van Royen A, Rövekamp MH, van Dongen RJAM, van de Schoot JB, Hardeman RM. In-111- leukocyte scintigraphy in the diagnosis of vascular graft infection. In: Hardeman MR, Najean Y, eds 1984; Blood cells in nuclear medicine. Part I. cell kinetics and biodistribution. The Hague: Martinus Nijhoff, 341–347.Google Scholar
  53. 53.
    Becker W, Götz R, Heidbreder W, Bömer W. Indium-III white blood cell scan in the diagnosis of infectious complications in patients undergoing regular dialysis treatment. In: Bischof-Delaloye A, Blaufox MD, eds 1986; Radionulides in nephrology. Basel. Karger, 1915.Google Scholar
  54. 54.
    Cook PS, Datz EL, Disbro MA, Alazraki NP, Taylor AT. Pulmonary uptake in In-I11- leukocyte imaging: clinical significance in patients with suspected occult infection. Radiology 1984; 150: 557–61.PubMedGoogle Scholar
  55. 55.
    Saverymuttu SH, Philips G, Peters AM, Lavender JP. Indium-Ill-analogues leukocyte scanning in lobar pneumonia and lung abscesses. Thorax 1985: 40: 925–30.PubMedCentralPubMedGoogle Scholar
  56. 56.
    MacSweeney JE, Peters AM, Lavender JP. Indium labelled leukocyte scanning in pyrexia of unknown origin. Clin Radiol 1990; 42: 414–7.PubMedGoogle Scholar
  57. 57.
    Hawker RJ, Hall CE, Drole Z, Rhys-Evans PH. Indium-leukocyte imaging in true pyrexia of unknown origin. EurJ Nucl Med 1985; 10: 172–4.Google Scholar
  58. 58.
    Peters AM. The utility of Tc-99m-HMPAO leukocytes for imaging infection. Semin Nucl Med 1994; XXIV: 110–27.Google Scholar
  59. 59.
    Becker W, Schomann E, Fischbach W, Bömer W, Gruner KR. Comparison of Tc-99m- HMPAO and In-111-oxine labelled granulocytes in man: first clinical results. Nucl Med Commun 1988; 9: 435–47.PubMedGoogle Scholar
  60. 60.
    Saverymuttu, SH, Peters AM, Lavender JP. Clinical importance of enteric communications with abdominal abscesses. Br Med J 1985; 290: 23–7.Google Scholar
  61. 61.
    Arndt JW, Van der Sluys Veer A, Blok D, Niffioen G, Verspaget HW, Lamers CBHW, Pauwels EKJ. Prospective comparative study of Tc-99m-WBCs and indium-111 granulocytes for the examination of inflammatory bowel disease. J Nucl Med 1991; 32: 2029–34.Google Scholar
  62. 62.
    Allan RA, Sladen GE, Bassingham S, Lazarus C, Clarke SEM, Folgeman I. Comparison of simultaneous Tc-99m-HMPAO and In-Ill-oxine labelled white blood cell scan in the assessment of inflammatory bowel disease. Eur J Nucl Med 1993; 20: 195–200.PubMedGoogle Scholar
  63. 63.
    Currie DC, Saverymuttu SH, Peters AM, Needham SG, George P, Dhillon DP, lavender JP, Cole PJ. In-111-labelled granulocyte accumulation in respiratory tract of patients with bronchiectasis. Lancet 1987; 1: 1335–9.PubMedGoogle Scholar
  64. 64.
    Currie DC, Peters AM, Garbett ND, George P, Strickland B, Lavener JP, Cole PJ. In-111- labelled granulocyte scanning to detect inflammation in the lungs of patients with chronic sputum expectoration. Thorax 1990; 45: 5414.Google Scholar
  65. 65.
    Jonker N, Peters AM, Carpani de Kaski M, Hodgson Hi, Lavender JP. A retrospective study of granulocytic kinetics in patients with systemic vasculitis. J Nucl Med 1992; 33: 491–7.PubMedGoogle Scholar
  66. 66.
    Locher JT, Seybold K, Andres RY, Schubiger PA, Mach JP, Buchegger F. Imaging of inflammatory and infectious lesions after injection of radioiodinated monoclonal antigranulocyte antibodies. Nucl Med Commun 1986; 7: 659–70.PubMedGoogle Scholar
  67. 67.
    Joseph K, Höffken H, Dammann V. ln-vivo-Markierung von Granulozyten mit Tc-99m-markierten monoklonalen Antikörpern: erste klinische Ergebnisse. NucCompact 1987; 18: 223–6.Google Scholar
  68. 68.
    Becker W, Blair J, Behr T, Repp R, Streckenbach H, Beck H, Gramatzki M, Winship MJ, Goldenberg DM, Wolf F. Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled antigranulocyte monoclonal antibody fragment. J Nuc Med 1994; 35: 143–643.Google Scholar
  69. 69.
    Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med 1994; XXIV: 1–13.Google Scholar
  70. 70.
    Becker W, Palestro CJ, Winship J, Feld T, Pinsky CM, Wolf F, Goldenberg DM. Rapid imaging of infections with a monoclonal antibody fragment (Leukoscan). Clin Orth Rel Res 1996; 329: 263–72.Google Scholar
  71. 71.
    Gratz S, Braun HG, Behr TM, Meller J, Hermann A, Conrad M, Rathmann D, Bertagnoli R, Willett HG, Becker W. Photopenia in chronic vertebral osteomyelitis with technetium-99m antigranulocyte antibody (BW 250/183). J Nucl Med 1997; 98: 211–6.Google Scholar
  72. 72.
    Becker W, Fleig W, Marienhagen J, Hahn E, Wolf F. Diagnostische Bedeutung der intestinalen Aktivität bei der Immunszintigraphie mit Tc-99m-NCA-95-Antikörpern. Nukl Med 1990; 229: 47–8.Google Scholar
  73. 73.
    Segarra I, Roca M, Baliellas C, Vilar L, Rican Y, Mora J. Puchal R, Martin-Comm J. Granulocyte-specific monoclonal antibody technetium-99m BW 250/183 and In-111-oxine labelled leukocyte scintigraphy in inflammatory bowel diasease. Eur J Nuc Med 1991; 18: 715–9.Google Scholar
  74. 74.
    Almers S, Granerus G, Franzen L, Strom M. Technetium-99m scintigraphy: more accurate assessment of ulcerative colitis with exametazime-labelled leukocytes than with antigranulocyte antibodies. Eur J Nucl Med 1996; 23: 247–55.PubMedGoogle Scholar
  75. 75.
    Cordes M, Hepp W, Langer R, Pannhorst J, Hierholzer J, Felix R. Vascular graft infection: detection by 1–123-labeled antigranulodyte antibody (anti-NCA-95) scintigraphy. Nucl Med 1991:30: 173–7.Google Scholar
  76. 76.
    Munz DL, Morguet AJ, Sandrock D, Heim A, Sold G, Figulla HR, Kreuzer H, Emrich D. Radioimmunoimaging of subacute infective endocarditis using a technetium-99m monoclonal granulocyte specific antibody. EurJ Nucl Med 1991; 18: 977–80.Google Scholar
  77. 77.
    Lind P, Langsteger W, Költringer P, Dimai HP, Passl R, Eber O. Immunoscintigraphy of inflammatory process with a technetium-99m-labelled monoclonal antigranulocyte antibody (Mab BW 250/183). J Nucl Med 1990; 31: 417–23.PubMedGoogle Scholar
  78. 78.
    Prvulovich EM, Miller RF, Costa DC, Severn A, Corbett E, Bomanij J, Becker WS, Ell PI. Immunoscintigraphy with a Tc-99m-labelled antigranulocyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS. AIDS 1995; 16: 838–45.Google Scholar
  79. 79.
    Rubin RH, Young LS, Hansen P, Nedelman M, Wilkinson R, Nelles MJ, Callahan R, Khaw BA, Strauss HW. Specific and nonspecific imaging of localized Fisher immunotype 1. Pneudomas aeruginosa infection with radiolabeled monoclonal antibody. J Nucl Med 1988; 29: 651–6.PubMedGoogle Scholar
  80. 80.
    Buscombe JR, Oyen WJG, Miller RF, Grant A, Claessens RAMJ, Van der Meer J, Corstens FMH, Ell JP, Miller RF. Indium-I11 labeled human polyclonal immunoglobulin identifying focal infection in patients positive for human immunodeficiency virus (HIV). J Nucl Med 1993; 34: 1621–5.PubMedGoogle Scholar
  81. 81.
    Corstens FHM, Claessens RAMJ. (1992) Imaging inflammation with human polyclonal immunoglobulin: not looked for, but discovered. Eur J Nucl Med 1992; 19: 155–8.PubMedGoogle Scholar
  82. 82.
    Claessens RAMJ, Koenders EB, Boerman OC, Oyen, WJG, Bonn GF, Van der Meer JWM, Corstens FHM. Dissociation of indium from indium-111-labelled diethylene triamine pentaacetic conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. Eur J Nucl Med 1995; 22: 212–9.PubMedGoogle Scholar
  83. 83.
    Juweid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglo-bulin G at focal sites of inflammation. Eur J Nucl Med 1992; 19: 159–65.PubMedGoogle Scholar
  84. 84.
    Oyen WJG, van Horn JR, Claessens RAMJ, Slooff TJJH, Van der Meer WMJ, Corstens FMH. Diagnosis of bone, joint and joint prothesis infections with indium-111 labelled human immunoglobulin G scintigraphy. Radiology 1992; 182: 195–9.PubMedGoogle Scholar
  85. 85.
    Oyen WIG, van Horn JR, Claessens RAMJ, Slooff TJJH, Van der Meer JWM. Diagnosing prosthetic joint infections. J Nucl Med 1991; 32: 2195–6.PubMedGoogle Scholar
  86. 86.
    De Kleijn EMHA, Oyen WJG, Claessens RAMJ, Corstens FMH, Van der Meer JWM. Scintigraphy with In-ill labeled polyclonal human immunoglobulin G (In-Ill-IgG) on patients with fever of unknown origin (FUO). Nucl Med Commun 1992; 13: 626.Google Scholar
  87. 87.
    Saptogino A, Becker W, Wolf F. Biokinetics and estimation of dose from Tc-99m-labelled polyclonal human immunoglobulin (HIG). Nucl Med 1991; 30: 18–23.Google Scholar
  88. 88.
    Buscombe JR, Miller RF, Lui D, Ell PJ. Combined Ga-67-citrate and Tc-99m human immunoglobulin imaging in human immunodeficiency virus-positive patients with fever of unknown origin. Nucl Med Commun 1991; 12: 583–92.Google Scholar
  89. 89.
    Spinelli F, Milella M, Sara R, Bagni F, Possa M, Vigorelli R. The value of Tc-99m-labelled human immunoglobulin scanning in the evaluation of Crohn’s disease. Eur J Nucl Med 1994; 35: 1436–43.Google Scholar
  90. 90.
    Sciuk J, Braundau W, Vollet B, Stucker R, Erlemann R, Bartenstein P, Peters PE, Schober O. Comparison of technetium-99m polyclonal human immunoglobulin and technetium-99m monoclonal antibodies for imaging chronic osteomyelitis. Eur J Nucl Med 1991; 18: 401–7.PubMedGoogle Scholar
  91. 91.
    Breedveld FC, Kroonenburgh MJPG, Camps JAJ, Feitsma HIJ, Markusse HM, Pauwels EKJ. Imaging of inflammatory arthritis with technetium-99m-labelled IgG. J Nucl Med 1989; 30: 2017–21.PubMedGoogle Scholar
  92. 92.
    Berna L, Torres G, Diez C, Estorch M, Martinez-Duncker D, Carrio I. Technetium-99m human polyclonal immunoglobulin G studies and conventional bone scans to detect active joint inflammation in chronic rheumatoid arthritis. Eur J Nucl Med 1992; 19: 173–6.PubMedGoogle Scholar
  93. 93.
    De Bois MHW, Arndt JW, Tak PP, Kluin PM, Van der Velde EA, Pauwels EKJ, Breedveld FC. Tc-99m-labelled polyclonal human immunoglobulin G scintigraphy before and after intraarticular knee injection of triamcinolone hexacetonide in patients with rheumatoid arthritis. Nucl Med Commun 1993; 14: 883–7.PubMedGoogle Scholar
  94. 94.
    De Bois MHW, Arndt JW, Van der Velde EA, Pauwels EKJ, Breedveld FC. Joint scintigraphy for quantification of synovitis with Tc-99m-labelled human immunoglobulin G compared to late phase scintigraphy with Tc-99m-labelled diphosphonate. Br J Rheumatol 1994; 33: 67–73.PubMedGoogle Scholar
  95. 95.
    Tahara T; Ichiya Y; Kuwabara Y et al. High [18F1-fluorodeoxyglucose uptake in abdominal abscesses: a PET study. J Comput Assist Toraogr 1989; 13: 829–831.Google Scholar
  96. 96.
    Osman S, Danpure HJ. The use of 2-[18F]FIuoro-2-deoxy-D-glucose as a potentialin vitroagent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Radiat Appl lnstrum [Part B] 1992; 19: 183–90.Google Scholar
  97. 97.
    Forstrom LA, Mullan BP, Hung JC, Lowe VJ, Thorson LM.18F-FDG labelling of human leucocytes. Nucl Med Commun 2000; 21: 691–4.PubMedGoogle Scholar
  98. 98.
    Lehmann K, Meller J, Behe M, Becker W. F-18-FDG Uptake in Granulozyten: Basis der F-18- FDG Szintigraphie. Nuklearmedizin 2001; 40: V168.Google Scholar
  99. 99.
    Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-l8-fluorodeoxyglucosein vivo:high accumulation in macrophages and granulocytes studied by microautoradiography. J Nucl Med 1992; 33: 1972–80.PubMedGoogle Scholar
  100. 100.
    Jones HA, Sriskandan S, Peters AM, Pride NB, Krausz T, Boobis AR, Haslett C. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J 1997; 10: 795–803.PubMedGoogle Scholar
  101. 101.
    Shreve P. Focal fluorine-l8-fluorodeoxyclucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 1998; 25: 259–64.PubMedGoogle Scholar
  102. 102.
    Lewis PI, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647–9.PubMedGoogle Scholar
  103. 103.
    Ichiya Y, Kuwabara Y, Sasaki Yoshida T, Akashi Y, Murayama S, Nakamura K, Fukumura T, Masuda K. FDG-PET in infectious lesions: detection and assessment of lesion activity. Ann Nucl Med 1996; 10: 185–91.PubMedGoogle Scholar
  104. 104.
    Sugawara Y; Braun DK; Kison PV; Russo JE; Zasadny KR; Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998; 259: 1238–43.Google Scholar
  105. 105.
    Bakheet SM, Powe J. Fluorine-18-fluorodeoxyglucose uptake in rheumatoid arthritis-associated lung disease in a patient with thyroid cancer. J Nucl Med 1998; 39: 234–6.PubMedGoogle Scholar
  106. 106.
    Metier J, Altenvoerde G, Munzel U, Jauho A, Behe M, Gratz S, Luig H, Becker W. Fever of unknown origin-prospective comparison of 18 FDG- imaging with a double head coincidence camera (DHCC) and Ga-67 citrate SPECT. Eur J Nucl Med 2000; 27: 1617–25.Google Scholar
  107. 107.
    Meller J, Lehmann K, Sahlmann C, Altenvoerde G, Meyer I, Behe M, Becker W. F-18-FDG bei der Abklärung postoperativer Fieberzustände. Nuklearmedizin 2001; 40: V167.Google Scholar
  108. 108.
    O’Doherty MJ, Barrington SF, Campbell M. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38: 1575–83.PubMedGoogle Scholar
  109. 109.
    Guhlmann A, Brecht Krauss D, Suger G. Fluorine-l8-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med 1998; 39: 2145–52.PubMedGoogle Scholar
  110. 110.
    Zhuang H, Duarte PS, Pourdehand M, Shnier D, Alavi A. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med 2000; 25: 281–4.PubMedGoogle Scholar
  111. 111.
    Kalicke T, Schmitz A, Risse JH, Arens S, Keller E, Hansis M, Schmitt O, Biersack HJ, Grünwald F. Fluorine-l8 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med 2000; 27: 524–528.PubMedGoogle Scholar
  112. 112.
    Van de Wiele C, Vandenberghe S, de Bondt P, de Clercq D, D’Asseler Y, Dierckx R. Coincidence camera FDG imaging for the diagnosis of chronic orthopedic infections: a feasibility study. J Comput Assist Tomogr 2001; 25: 184–9.PubMedGoogle Scholar
  113. 113.
    Metier J, Ivancevic V, Conrad M, Gratz S, Munz DL, Becker W. Clinical value of immunoscintigraphy in patients with fever of unknown origin. J Nucl Med 1998; 39; 1248–53.Google Scholar
  114. 114.
    Arnow PM, Flaherty JP. Fever of unknown origin. Lancet 1997; 350: 575–80.PubMedGoogle Scholar
  115. 115.
    Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis 1997; 24: 291–302.PubMedGoogle Scholar
  116. 116.
    Knockaert DC. Fever of unknown origin, a literature survey. Acta Clin Belg 1992; 47: 42–57.PubMedGoogle Scholar
  117. 117.
    Cunha BA. Fever of unknown origin. Infect Dis Clin North Am 1996; 10: 1 I 1–27.Google Scholar
  118. 118.
    Whitehead TC, Davidson RN. Pyrexia of unknown origin: changing epidemiology. Curr Opin Infect Dis 1997; l0: 134–8.Google Scholar
  119. 119.
    Durack DT, Street AC. Fever of unknown origin - reexamined and redefined.CuffClin Top lnf Dis 1991; 11:35–51.Google Scholar
  120. 120.
    Armstrong WS, Katz JT and Kazanjian PH. Human immunodeficiency virus-associated fever of unknown origin: a study of 70 patients in the United States and review. Clin Infect Dis 1999; 28: 341–5.PubMedGoogle Scholar
  121. 121.
    Chang FT, Singh N, Cayowski. Fever in liver transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis 1998; 26: 59–65.PubMedGoogle Scholar
  122. 122.
    Pizzo PA. Fever in immunocompromised patients. N Engl J Med 1999; 341: 893–900.PubMedGoogle Scholar
  123. 123.
    Li JS, Sexton DJ, Mick N. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30: 633–8.PubMedGoogle Scholar
  124. 124.
    Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals. Clin Infect Dis 1992; 15: 968–73.PubMedGoogle Scholar
  125. 125.
    Jung A, Singh MM, Jajoo U. Unexplained fever-analysis of 233 cases in a referral hospital. Indian J Med Sci 1999; 53: 535–44.PubMedGoogle Scholar
  126. 126.
    De Kleijn EMH, Vandenbroucke JP, Van Der Meer JWM and the Netherlands FUO Study Group. Fever of unknown origin (FUO). Medicine 1997; 76:392–400.Google Scholar
  127. 127.
    De Kleijn EMH, Van Lier HJJ, van der Meer JWM and the Netherlands FUO study group. Fever of unknown origin (FUO). Medicine 1997; 76: 401–14.Google Scholar
  128. 128.
    Peters AM. Nuclear medicine imaging in fever of unknown origin. Q J Nucl Med 1999; 43: 61–73.PubMedGoogle Scholar
  129. 129.
    Corstens FHM, van der Meer JWM. Nuclear medicine’s role in infection and inflammation. Lancet 1999;43; 354–70.Google Scholar
  130. 130.
    Palestro CJ, Torres MA. Radionuclide imaging of nonosseous infection. Q J Nucl Med 1999; 43: 46–60.PubMedGoogle Scholar
  131. 131.
    De Kleijn EM, Oyen WJ, Corstens FH, van der Meer JW. Utility of indium-111-labeled polyclonal immunoglobulin G scintigraphy in fever of unknown origin. The Netherlands FUO Imaging Group. J Nucl Med 1997; 38: 484–9.PubMedGoogle Scholar
  132. 132.
    Knockaert DC, Mortelmans LA, De Roo MC, Bobbaers HJ. Clinical value of Gallium-67 scintigraphy in evaluation of fever of unknown origin. Clin Infect Dis 1994; 18: 601–5.PubMedGoogle Scholar
  133. 133.
    Knockaert DC, Mortelmans LA, Deroo MC, Bobbaers HJ. Clinical value of Gallium-67 scintigraphy in the investigation of fever or inflammation of unknown origin in the ultrasound and computed tomography era. Acta Clin Belg 1989; 44: 91–8.PubMedGoogle Scholar
  134. 134.
    Sfakianakis GN, Al-Shikh W, Heal A, Rodman G, Zeppa R, Serafini A. Comparisons of scintigraphy with In-111 leukocytes and Ga-67 in the diagnosis of occult sepsis. J Nucl Med 1982; 23: 618–26.PubMedGoogle Scholar
  135. 135.
    Goodwin DA. Clinical use of In-111 leukocyte imaging. Clin Nucl Med 1983; 8: 449–55.Google Scholar
  136. 136.
    Blockmans D, Knockaert D, Maes A. Clinical value of (18F)fluoro-deoxyglucose postron emission tomography for patients with fever of unknown origin. Clin Inf.Dis 2001; 32: 191–6.Google Scholar
  137. 137.
    Lorenzen J, Buchert R, Bohuslavizki KH. Value of FDG PET in patients with fever of unknown origin. Nucl Med Comm 2001; 22: 779–83.Google Scholar
  138. 138.
    Rubin RH, Fischman Ai. Radionuclide imaging of infection in the immunocompromised host. Clin Infect Dis 1996; 22: 414–22.PubMedGoogle Scholar
  139. 139.
    McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in Mortality due to invasive mycotic Diseases in the United States, 1980–1997. Clin Infect Dis 2001; 33: 641–7.PubMedGoogle Scholar
  140. 140.
    Walsch T.I, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989; 5: 131–42.Google Scholar
  141. 141.
    Nicod LP, Pache JC, Howarth N. Fungal infections in transplant recipients. Eur Resp J 2001; 17: 133–40.Google Scholar
  142. 142.
    Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988; 11: 4 11–26.Google Scholar
  143. 143.
    Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805.PubMedGoogle Scholar
  144. 144.
    Bodey GP, Vartivian S. Aspergillosis. Eur J Microbiol Infect Dis 1989; 8: 413–37.Google Scholar
  145. 145.
    Young RC, Bennet JE, Vogel CL, Carbone PP, De Vita VT. Aspergillosis: the spectrum of the disease in 98 patients. Medicine 1970; 49: 147–73.PubMedGoogle Scholar
  146. 146.
    Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999; 29: 239–44.PubMedGoogle Scholar
  147. 147.
    Banerjee S N, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards, Tolson J, Henderson T, Marone WI, and the National Nosocomial Infections Surveillance System. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. Am J Med 1991; 91: 86S–89S.PubMedGoogle Scholar
  148. 148.
    Chen KY, Shian SC, Hsueh PR, Luh KT, Yang PC. Pulmonary fungal infection: Emphasis on microbiological spectra, patient outcome and prognostic factors. Chest 2001; 120: 177–84.PubMedGoogle Scholar
  149. 149.
    Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001; 33: 187–90.PubMedGoogle Scholar
  150. 150.
    Hams DE, Enterline DS. Fungal infections of the central nervous system. Neuroimaging Clin N Am 1997; 7: 297–320.Google Scholar
  151. 151.
    Awashti M, Patankar T, Shah P, Castillo M. Cerebral cryptococcosis: atypical appearances on CT. Br J Radiol 2001; 74: 83–5.Google Scholar
  152. 152.
    Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for PCP. Seminars of respiratory infection 1997; 12: 70–78.Google Scholar
  153. 153.
    Bekerman C, Nayak SM. Gallium imaging. In: Henkin RE, Boles MA, Dillehay GL, Halama JR, Karesh SM, Wagner RH, Zimmer AM (Eds). Nuclear Medicine. St Louis. Mosby, 1996. 1597–1618.Google Scholar
  154. 154.
    WalzerPD.Pneumocystis carinii pneumonia. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (Eds). Harrison’s principles of internal medicine (13th edition). New York. Mc Graw-Hill, 1994. 908–910.Google Scholar
  155. 155.
    Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, Rothrock GA, Pfaller MA, Pinner RW, Hajjeh RA. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164–70.PubMedGoogle Scholar
  156. 156.
    Beck-Sagué CM, Jarvis WM, and The National Nosocomial Infections Surveillance System. Secular Trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J Infect Dis 1993; 167: 1247–51.Google Scholar
  157. 157.
    Centers for disease control and prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. Morb Mortal Wkly Rep 1989; 38: 1–9.Google Scholar
  158. 158.
    Groll AH, Shah PM, Mentzel C, Schneider M, Just-Neubling G, Huebling G, Huebner K. Trends in postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23–32.PubMedGoogle Scholar
  159. 159.
    Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill JR. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Aspergillus Study Group. Medicine 2000; 79: 250–60.PubMedGoogle Scholar
  160. 160.
    Pizzo PA. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 1993; 328: 1323–32.PubMedGoogle Scholar
  161. 161.
    Montesinos J, Sola C, Maroto P, Salazar R, BalmanaJRamirez A, Pardo B, Pencas R, Gurgui M, Lopez-Lopez JJ. Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Eur J Clin Microb Infect Dis 2002 (in press).Google Scholar
  162. 162.
    Bille J. Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients. Ent J Antimicrob Agents. 2000; 16: 87–89.Google Scholar
  163. 163.
    Reimer LG, Carroll KC. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections. Clin Infect Dis 1998; 26: 742–8.PubMedGoogle Scholar
  164. 164.
    Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001;97:1604–10.PubMedGoogle Scholar
  165. 165.
    Kami M, Tanaka Y, Kanda Y, Ogawa S, Masumoto T, Ohtomo K, Matsumura T, Saito T, Machida U, Kashima T, Hirai H. Computed tomographic scan of the chest, latex agglutination test and plasma (1–3)-13-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 2000; 85: 745–52.PubMedGoogle Scholar
  166. 166.
    Einsele H, Hebart H, Roller G, Loftier J, Rothenhofer I, Muller CA, Bowden RA, van Burik J, Engelhard D, Kanz L, Schumacher U. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35: 1353–60.PubMedCentralPubMedGoogle Scholar
  167. 167.
    Turbiner EH, Yeh SD, Rosen PP, Bains MS, Benua RS. Abnormal gallium scintigraphy in pneumocystis carinii pneumonia with a normal chest radiograph. Radiology 1978; 127: 437–8.PubMedGoogle Scholar
  168. 168.
    Blum U, Windfuhr M, Buitrago-Tellez C, Sigmund G, Herbst EW, Langer M. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest 1994; 106: 1156–61.PubMedGoogle Scholar
  169. 169.
    Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, Lopez J, Couillault G, Picard F, Wagner O, Guy H. Increasing Volume and Changing Characteristics of Invasive Pulmonary Aspergillosis on Sequential Thoracic Computed Tomography Scans in Patients With Neutropenia. J Clin Oncol 2001; 19: 253–9.PubMedGoogle Scholar
  170. 170.
    Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis 1997; 16: 424–6.PubMedGoogle Scholar
  171. 171.
    Sallustio G, Pagano L, Ortu La Barbera E, Morace G, Macis G, Pagliari G, Pirronti T. Pulmonary aspergillosis in patients with hematologic malignancies: clinicoradiologic correlation. Rays 1994; 19: 465–78.PubMedGoogle Scholar
  172. 172.
    Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 60–2.Google Scholar
  173. 173.
    Dromer F. Cryptococcosis. Rev Prat 2001; 51: 738–41.PubMedGoogle Scholar
  174. 174.
    Barron TF, Bimbaum NS, Shane LB, Goldsmith SJ, Rosen MJ. Pneumocystis carinii pneumonia studied by gallium-67 scanning. Radiology 1985; 154: 791–3.PubMedGoogle Scholar
  175. 175.
    Reiss TF, Golden J. Abnormal lung gallium-67 uptake preceding pulmonary physiologic impairment in an asymptomatic patient with Pneumocystis carinii pneumonia. Chest 1990; 97: 1261–3.PubMedGoogle Scholar
  176. 176.
    Rubin RH, Young LS, Hansen WP. Specific and nonspecific imaging of localized Fisher immunotype 1 Pseudomonas aeruginosa infection with radiolabeled antibody. J Nucl Med 1988; 29: 651–6.PubMedGoogle Scholar
  177. 177.
    Welling MM, Lupetti A, Baiter HS, Lanzerri S, Soutu B, Rey AM, Savio EO, PaulusmaAnnema A, Pauwels EKJ, Nibbering PH. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001; 42: 788–94.PubMedGoogle Scholar
  178. 178.
    Chianelli M, Mather SJ, Martin-Comin J, Signore A. Radiopharmaceuticals for the study of inflammatory processes: a review. Nucl Med Commun. 1997; 18: 437–55.Google Scholar
  179. 179.
    Santiago JF, Jana S, Gilbert HM. Role of Fluorine-l8-fluorodeoxyglucose in the work-up of febrile AIDS patients: experience with dual head coincidence imaging. Clin Pos [’nag 1999; 2: 3013–29.Google Scholar
  180. 180.
    Blockurans D, Knockaert D, Maes A. Clinical value of [I8F] fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191–6.Google Scholar
  181. 181.
    Parthasarathy KL, Bakshi SP, Bender MA. Radiogallium scan in P. carinii pneumonia. Clin Nucl Med 1982; 7: 71–4.PubMedGoogle Scholar
  182. 182.
    Moses SC, Baker SR, Seldin MF. Diffuse pulmonary gallium accumulation with a normal chest radiogram in a homosexual man with Pneumocystis carinii pneumonia. A case report. Clin Nucl Med 1983; 8: 608–9.PubMedGoogle Scholar
  183. 183.
    Levenson SM, Warren RD, Richman SD, Johnston GS, Chabner BA. Abnormal pulmonary gallium accumulation in P. carinii pneumonia. Radiology 1976; 119: 395–8.PubMedGoogle Scholar
  184. 184.
    Fineman DS, Palestro CJ, Kim CK, Needle LB, Vallabhajosula S, Salomon RW, Goldsmith SJ. Detection of abnormalities in febrile AIDS patients with In-111-labeled leukocyte and Ga-67 scintigraphy. Radiology 1989; 170: 677–80.PubMedGoogle Scholar
  185. 185.
    Love C, Patel M, Lonner BS, Tomas MB, Palestro CJ. Diagnosing spinal osteomyelitis: a comparison of bone and Ga-67 scintigraphy and magnetic resonance imaging. Clin Nucl Med. 2000; 25: 963–77.PubMedGoogle Scholar
  186. 186.
    Giorgi MC, Camargo EE, Pinto WP, Del Negro G. Gallium-67 imaging in the diagnosis of blastomycosis. Eur J Nucl Med 1987; 13: 300–4.PubMedGoogle Scholar
  187. 187.
    Moreno AJ, Brazier JM, Baker FJ, Fox BJ, Pittman DL. Gallium-67 localization in disseminated sporotrichosis. Clin Nucl Med 1985; 10: 424–6.PubMedGoogle Scholar
  188. 188.
    Rao GM, Guruprakash GH, Bhaskar G. Localization of gallium-67 in aspergilloma. J Nucl Med 1979; 20: 900.PubMedGoogle Scholar
  189. 189.
    Boerman OC, Dams ET, Oyen WJ, Corstens FH, Storm G. Radiophannaceuticals for scintigraphie imaging of infection and inflammation. Inflamm Res 2001; 50: 55–64.PubMedGoogle Scholar
  190. 190.
    Vasquez TE, Evans DG, Schiffinan H, Ashburn WL. Fungal splenic abscesses in the immunosuppressed patient. Correlation of imaging modalities. Clin Nucl Med 1987; 12: 36–8.PubMedGoogle Scholar
  191. 191.
    Haseman MK, Blake K, McDougall IR. Indium-I11 WBC scan in local and systemic fungal infections. Arch Intern Med 1984; 144: 1462–3.PubMedGoogle Scholar
  192. 192.
    Sunshine JL, Gentili A. Imaging of disseminated infection by a rare fungal pathogen, Fusarium. Clin Nucl Med 1994; 19: 435–7.PubMedGoogle Scholar
  193. 193.
    Britton KE, Vinjamuri S, Hall AV, Solanki K, Siraj QH, Bomanji J, Das S. Clinical evaluation of technetium-99m infecton for the localisation of bacterial infection. Eur J Nucl Med 1997; 24: 553–6.PubMedGoogle Scholar
  194. 194.
    Vanninen E, Korppi M, Bergstrom KA, Lansimies E. Detection of focal inflammation with Tc-99m HMPAO labeled leukocytes in children. Clin Nucl Med 1993; 18: 570–2.PubMedGoogle Scholar
  195. 195.
    Franzius C, Biermann M, Hulskamp G, Frosch M, Roth J, Sciuk J, Schober O. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med 2001; 26: 232–3.PubMedGoogle Scholar
  196. 196.
    Ozsahin H, von Planta M, Muller I, Steinert HC, Nadal D, Lauener R, Tuchschmid P, Willi UV, Ozsahin M, Crompton NE, Seger RA. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998; 92: 2719–24.PubMedGoogle Scholar
  197. 197.
    Ho AY, Pagliuca A, Maisey MN. Positron emission scanning with 18-FDG in the diagnosis of deep fungal infections. Br J Haematol 1998; 101: 392–3.PubMedGoogle Scholar
  198. 198.
    Lupetti A, Welling MM, Mogera S, Paulusma-Annema A, Nibbering PH, Pauwels EKJ. Imaging of fungal infections with 99mTc-labeled fluconazole and antimicrobial peptides. Eur J Nucl Med 2000; 27: OS 306.Google Scholar
  199. 199.
    Béhé M, Trorp B, Schaffrinski M, Behr TM, Angerstein C, Laatsch H, Rüchel R, Becker W. Iodinated blankophor specifically detects fungal infection. Eur J Nucl Med 1999; 26: OS 178.Google Scholar
  200. 200.
    Wills EA, Redinbo MR, Perfect JR, Del Poeta M. New potential targets for antifungal development. Expert Opin Ther Targets 2000; 4: 1–32:265.Google Scholar
  201. 201.
    Bretagne S, Marmorat-Khuong A, Kuentz M, Latge J-P, Bart-Delabesse E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by sandwich ELISA: practical use in neutropenic patients. J Infect 1997; 35: 7–15.PubMedGoogle Scholar
  202. 202.
    Becker MJ, de Mane S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000; 38: 1434–8.PubMedCentralPubMedGoogle Scholar
  203. 203.
    Denning DW. Early diagnosis of invasive aspergillosis. Lancet 2000; 355(9202): 423–4.PubMedGoogle Scholar
  204. 204.
    Sendid B, Tabouret M, Poirot JL, Mathieu D, Fruit J, Poulain D. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999; 37: 1510–7.PubMedCentralPubMedGoogle Scholar
  205. 205.
    van Etten EW, Snijders SV, van Vianen W, Bakker-Woudenberg IA. Superior efficacy of liposomal amphotericin B with prolonged circulation in blood in the treatment of severe candidiasis in leukopenic mice. Antimicrob Agents Chemother 1998; 42: 2431–3.PubMedCentralPubMedGoogle Scholar
  206. 206.
    Yoshida Y. Cytochrome P450 of fungi: primary target for azole antifungal agents. Curr Top Med Mycol 1988; 2: 388–418.PubMedGoogle Scholar
  207. 207.
    Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovascular Res 1996; 32: 733–42.Google Scholar
  208. 208.
    Brown EJ. Adhesive interaction in the immune system. Trends Cell Biol 1997. 7:289–95.PubMedGoogle Scholar
  209. 209.
    Petruzzelli L, Takami M, Humes D. Structure and function of cell adhesion molecules. Am J Med 1999, 106: 467–76.PubMedGoogle Scholar
  210. 210.
    Kevil CG, Bullard DC. Roles of leukocytes/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Am J Med 1999; 106: 677–87.PubMedGoogle Scholar
  211. 211.
    Ransohoff R. Mechanism of inflammation in MS tissue: adhesion molecules and chemokines. J Neuroimmunol 1999, 98: 57–68.PubMedGoogle Scholar
  212. 212.
    Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today 1992; 13: 106–12.PubMedGoogle Scholar
  213. 213.
    Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993; 11: 767–804.Google Scholar
  214. 214.
    Mason JC, Haskard DO. The clinical importance of leukocytes and endothelial cell adhesion molecules in inflammation. Vasc Med Rev 1994; 5: 249–75.Google Scholar
  215. 215.
    Reubi JC, Waser B, Markusse HM, Krenning EP, Van Hagen M, Laissue JA. Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 1994; 27: 371–8.Google Scholar
  216. 216.
    Curtis SB, ChenJCWinkelaar G, Turnbull RG, Hewitt J, Buchan AM, Hsiang YN. Effect of endothelial and adventitial injury on somatostatin receptor expression. Surgery 2000; 127: 577–83.PubMedGoogle Scholar
  217. 217.
    Jamar F, Chapman PT, Manicourt DH, Glass DM, Haskard DO, Peters AM. A comparison between 111 In anti-E-selectin MoAb and9inTc-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis. Br J Radiology 1997; 70: 473–81.Google Scholar
  218. 218.
    Krenning E, Kwekkeboom D, Pauwels S, Kvols L, Reubi J. Somatostatin receptor scintigraphy. In: Freeman LM, Weissman H, (eds). Nucl Med Annual. New York, Raven Press 1995; 1–50.Google Scholar
  219. 219.
    Reubi J, Waser B, Horisberger U.In vitroautoradiographic andin vivoscintigraphic localisation of somatostatin receptors in human lymphatic tissue. Blood 1993; 82: 2143–5 LPubMedGoogle Scholar
  220. 220.
    Reubi J, Mazzucchelli L, Laissue J. Intestinal vessels express a high density of somatostatin receptor in human inflammatory bowel disease. Gastroenterology 1994; 106: 951–9.PubMedGoogle Scholar
  221. 221.
    Van Hagen P, Markusse H, Lamberts S. Somatostatin receptor imaging the presence of somatostatin receptor in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1521–7.Google Scholar
  222. 222.
    Van Hagen P, Krenning E, Reubi J. Somatstatin analogue scintigraphy in granulomatous diseases. EurJ Nucl Med 1994; 21: 497–502.Google Scholar
  223. 223.
    Diaz M, Bockisch A, Kahaly G, Hahn K. Preliminary results of somatostatin receptor scintigraphy in endocrine ophtalmopathy. Eur J Nucl Med 1993; 20: 844.Google Scholar
  224. 224.
    Postema P, Wijnggaarde R, Vandenbosch W. Folow up in In-111-DTPA-D-Phe-1 octreotide scintigraphy in thyroidal and orbital Graves’ disease. J Nucl Med 1995; 36: 203P.Google Scholar
  225. 225.
    Eberhardt J, Hermann SO, Clausen M. Accumulation of 111In-Octreotide in the orbital and thyroid regions of patients with Graves’ disease and with exophtalmos. Eur J Nucl Med 1993; 20: 844.Google Scholar
  226. 226.
    Bohuslavizki K, rhmann SO, Brenner W. 111-In-octreotide imaging in patients with longstanding Graves’ ophthalmopathy. Nucl Med Commun 1995; 16: 912–6.PubMedGoogle Scholar
  227. 227.
    Bahn R, Heufelder A. Pathogenesis of Graves’ ophthalmopathy. N Eng J Med 1993; 329: 1468–75.Google Scholar
  228. 228.
    Hurley J. Orbitopathy after treatment of Graves’ disease. J Nucl Med 1994; 35: 918–20.PubMedGoogle Scholar
  229. 229.
    Oyen W, Boerman O, Claessens R, Meer Jvd, Corstens F. Is somatostatin receptor scintigraphy suited for the detection of acute infection disease? Nucl Med Comm 1994; 15: 289–93.Google Scholar
  230. 230.
    Reubi J. Neuropeptide receptors in health and disease the molecular basis forin vivoimaging. J Nucl Med 1995; 36: 1825–35.PubMedGoogle Scholar
  231. 231.
    Breeman W, Hagen Mv, Visser H.In vitroandin vivostudies of substance P receptor expression in rats with the new analog [indium-Ill-DTPA-Argl] substance P. J Nucl Med 1996; 37: 108–17.PubMedGoogle Scholar
  232. 232.
    De Fougerolles A.R, Chi-Rosso G, Bajardi A, Gotwals P Green CD, Koteliansky VE. Global expression analysis of extracellular matrix-integrin interaction in monocytes. Immunity 2000; 13: 749–58.PubMedGoogle Scholar
  233. 233.
    Natham C, Sporn M. Cytokines in Context. J Cell Biology. 1991; 113: 981–6.Google Scholar
  234. 234.
    Opdenakker G, van den Steen PE, Van Damme J. Gelatinase B. A tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571–9.PubMedGoogle Scholar
  235. 235.
    Crone C, Levitt DJ. Capillary permeability to small solutes. In Renkin EM, Michel CC (eds). The cardiovascular system. Bethesda. The American Physiological Society, 1984: 411–66.Google Scholar
  236. 236.
    Trap-Jensen J, Lassen NA. Restricted diffusion in skeletal muscle capillaries in man. Am J Physiol 1971; 220: 373–6.Google Scholar
  237. 237.
    Rennen HJ, Makarewicz J, Oyen WJ, Lavennan P, Corstens FH, Boerman OC. The effect of molecular weight on nonspecific accumulation of (99m)Tc-labeled proteins in inflammatory foci. Nucl Med Biol 2000; 28: 401–8.Google Scholar
  238. 238.
    Hnatovich D, Virzi F, Ruskowski M. Investigation of avidin and biotin for imaging inflammation. J Nucl Med 1987; 28: 1294–302.Google Scholar
  239. 239.
    Rusckowski M, Fritz B, Hnatowich D. Localization of infection using streptavidin and biotin, an alternative to nonspecific polyclonal immunoglobulin. J Nucl Med 1992; 33: 1810–5.PubMedGoogle Scholar
  240. 240.
    Samuel A, Paganelli G, Chiesa R. Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med 1996; 37: 55–61.PubMedGoogle Scholar
  241. 241.
    Rusckowski M, Paganelli G, Hnatowich D. Imaging osteomyelitis with Streptavidin and Indium-1l 1-labeled biotin. J Nucl Med 1996; 37: 1655–62.PubMedGoogle Scholar
  242. 242.
    Lazzeri E, Manca M, Molea N, Marchetti S, Consoli V, Bodei L, Bianchi R, Chinol M, Paganelli G, Mariani G. Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients. Eur J Nucl Med 1999; 26: 606–14.PubMedGoogle Scholar
  243. 243.
    Boerman O, Storm G, Oyen W. Sterically stabilised liposomes labeled with indium-111 to image focal infection. J Nucl Med 1995; 36: 1639–44.PubMedGoogle Scholar
  244. 244.
    Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblast regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001; 4: 199–204.Google Scholar
  245. 245.
    Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997; 151: 317–21.PubMedCentralPubMedGoogle Scholar
  246. 246.
    Akbar AN, Lord JM, Salmon M. IFN-a and IFN-j3: a link between immune memory and chronic Inflammation. Immunol Today 2000; 21: 337–42.PubMedGoogle Scholar
  247. 247.
    Ward SG, Bacon K, Westwick J. Chemokine and T lymphocytes: More than attraction. Immunity 1998; 9: 1–11.PubMedGoogle Scholar
  248. 248.
    Hjelmström L. Lymphoid neogenesis:de novoformation of lymphoid tissue in chronic inflammation trough the expression of homing chemokines. J Leuk Biol 2001; 69: 331–9.Google Scholar
  249. 249.
    Roca M, Martin-Comm J, Becker W, Bernardo-Filho M, Gutfilen B, Moisan A, Peters M, Prats E, Rodrigues M, Sampson C, Signore A, Sinzinger H, Thakur M. A consensus protocol for white blood cells labelling with technetium99m hexamethylpropylene amine oxime. Eur J Nucl Med 1998 25: 797–9.PubMedGoogle Scholar
  250. 250.
    Pozzilli P, Pozzilli C, PantanoPNegri M, Andreani D, Cudworth AG. Tracking of indiumI11-oxine labelled lymphocytes in autoimmune thyroid disease. Clin Endocrinol Oxf 1983; 19: 111–6.PubMedGoogle Scholar
  251. 251.
    Kaldany A, Hill T, Wentworth S, Brink SJ, D’elia JA, Clouse M. Trapping of peripheral blood lymphocytes in the pancreas of patients in acute-onset insulin dependent diabetes mellitus. Diabetes 1982; 31: 463–6.PubMedGoogle Scholar
  252. 252.
    Gallina DL, Pelletier D, Doherty P, Koevary SB, Williams RM, Like AA, Chick WL, Rossini AA. I I I Indium-labelled lymphocytes do not image or label the pancreas of the BB/W rat. Diabetologia 1985; 28: 143–7.PubMedGoogle Scholar
  253. 253.
    Rubin PJ, Hartman JJ, Hasapes JP, Bakke JE, Bergmann SR. Detection of cardiac transplant rejection with 1111n-labeled lymphocytes and gamma scintigraphy. Circulation 1996; 94: 298–303.Google Scholar
  254. 254.
    Ten Berge RJM, Natarajan AT, Hardeman MR, van Royen EA, Schellekens P. Labelling with Indium-111 has detrimental effects on human lymphocytes: concise communication. J Nuc Med 1983; 24: 615–20.Google Scholar
  255. 255.
    Signore A, Beales P, Sensi M, Zuccarini O, Pozzilli P. Labelling of lymphocytes with Indium- II1-oxine: effect on cell surface phenotype and antibody-dependent cellular cytotoxicity. Immunol Letters 1983; 6: 151–4.Google Scholar
  256. 256.
    Read EJ, Keenan AM, Carter CS, Yolles PS, Davey RJ. In vivo traffic of indium-I I 1-oxine labeled human lymphocytes collected by automated lymphapheresis. J Nucl Med 1990; 31: 999–1006.PubMedGoogle Scholar
  257. 257.
    Jaakkola K, Knuuti J, Soderlund K, Saraste A, Jalkanen S, Voipio-Pulkki LM. Labelling lymphocytes with technetium”-hexamethyl propyleneamine oxime for scintigraphy: an improved labelling procedure. J Immunol Methods 1998; 214: 187–97.PubMedGoogle Scholar
  258. 258.
    Jorgensen C, Couret I, Bologna C, Rossi M, Sany J. Radiolabelled lymphocyte migration in rheumatoid synovitis. Ann Rheum Dis 1995; 54: 39–44.PubMedCentralPubMedGoogle Scholar
  259. 259.
    Swift RI, Danpure HJ, Osman S, Gaer J, Tsikos C, Peters AM. Imaging of metastatic colorectal cancer with tumour activated killer lymphocytes. Lancet 1991; 337: 1511–2.PubMedGoogle Scholar
  260. 260.
    Mazzoni G, Lee S, Tomer A, Gittes RF. Indium-labeled presensitised T cells for the diagnosis of graft rejection. J Surg Res 1992; 52: 85–8.PubMedGoogle Scholar
  261. 261.
    Signore A, Chianelli M, Toscano A, Monetini L, Ronga G, Nimmon CC. A radiopharmaceutical for imaging areas of lymphocitic infiltration: 123I-Interleukin-2. Labelling procedures and animal studies. Nucl Med Commun 1992; 13: 713–22.PubMedGoogle Scholar
  262. 262.
    Signore A, Chianelli M, Annovazzi A, Rossi M, Maiuri L, Greco M, Ronga G, Britton KE, Picarelli A. Imaging active lymphocytic infiltration in celiac disease with iodine-123interleukin-2 and the response to diet. Eur J Nucl Med 2000; 27: 18–24.PubMedGoogle Scholar
  263. 263.
    Signore A, Chianelli M, Annovazzi A, Bonanno E, Spagnoli LG, Pozzilli P, Pallone F, Biancone L. 1231-interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J Nucl Med 2000; 41: 242–9.PubMedGoogle Scholar
  264. 264.
    Signore A, Barone R, Procaccini E.In vivomeasurement of immunoglobulin accumulation in the pancreas of recent onset type 1 diabetic patients. Clin Exp Rheumatol 1996; 14: S41–S45.PubMedGoogle Scholar
  265. 265.
    Signore A, Chianelli M, Parisella MG, Giacalone P, Di Leve G, Barone R. In vivo imaging of insulitis in autoimmune diabetes. J Endocrinol Invest 1999; 22: 151–8.PubMedGoogle Scholar
  266. 266.
    Barone R, Chianelli M, Nardi G, Parisella M G, Di Leve G, Mire Sluis A, Signore A. Radiolabelled interleukin-12 p40. A new radiopharmaceutical for imaging chronic THImediated inflammation. Q J Nucl Med 1998; 42 (suppl) 1:77.Google Scholar
  267. 267.
    Adams DO, Hamilton TA. The cell biology of macrophage activation. Ann Rev Immunol 1984; 2: 283–318.Google Scholar
  268. 268.
    Stevenson HC, Keenan AM, Woodhouse C. Fate of Gamma-Interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. Cancer Res 1987; 47: 6100.PubMedGoogle Scholar
  269. 269.
    Andreesen R, Brugger W, Scheibenbogen C, Kreutz M, Meerpohl HG, Leser HG, Rehm A, Löhr GW. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: A new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450.PubMedGoogle Scholar
  270. 270.
    Lesimple T, Moisan A, Toujas L. Autologous macrophages and antitumour cell therapy. Res Immunol 1998; 149: 663.Google Scholar
  271. 271.
    Lesimple T, Moisan A, Guillé F, Leberre C, Audran R, Drenou B, Toujas L. Treatment of metastatic renal carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor. J Immunotherapy 2000; 23: 675.Google Scholar
  272. 272.
    Marienhagen J, Hennemann B, Andreesen R, Eilles C. I 1 1 In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: an in vitro evaluation. Nucl Med Comm 1995; 16: 357.Google Scholar
  273. 273.
    Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML, Lallot C, Eber JL, Bartholeyns J, Poindron P, Morand G, Witz, JP, Oberling F. Phase I trial of intravenous infusion ofex-vivoactivated autologous blood-derived macrophages in patient with non small cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol lmmunother 1991; 33: 319.Google Scholar
  274. 274.
    Andreesen R, Hennemann B, Krause SW. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998; 64: 419.PubMedGoogle Scholar
  275. 275.
    Hennemann B, Scheibenbogen C, Schumichen C, Andreesen R. Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol 1995; 18: 19.PubMedGoogle Scholar
  276. 276.
    Audran R, Collet B, Moisan A, Toujas L Fate of mouse macrophages radiolabelled with PKH- 95 and injected intravenously. Nucl Med Biol 1995; 22: 817.PubMedGoogle Scholar
  277. 277.
    Audran R, Lesimple T, Delamaire M, Picot C, Van Damme J, Toujas L. Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol 1996; 103: 155.PubMedCentralPubMedGoogle Scholar
  278. 278.
    Diot P, Pape AL, Nolibe D. Scintigraphy with JOOIX, a Klebsiella membrane glycolipid, for the early diagnosis of chronic berilliosis: results from an experimental model. Br J Ind Med 1992; 49: 359–64.PubMedCentralPubMedGoogle Scholar
  279. 279.
    Perin F, Pittet J, Hoffschir D. Scintigraphic potential of J00I X acylated polygalactoside for imaging inflammatory lesions in pigs. Nucl Med Biol 1993; 20: 963–71.PubMedGoogle Scholar
  280. 280.
    Goupille P, Valat JP, Le Pape A. Imaging of synovitis in rheumatoid arthritis with radionuclide tracer. J Rheumatol 1994; 21: 1975–6.PubMedGoogle Scholar
  281. 281.
    Miot-Noirault E, Perin F, Routledge L, Normier G, Pape AL. Macrophage targeting with technetium-99m labelled J00I acylated poly-galactoside for scintigraphy of inflammation: optimisation and assessment of imaging specificity in experimental arthritis. Eur J Nucl Med 1996; 23: 61–8.PubMedGoogle Scholar
  282. 282.
    Diot P, Lemari E, Baulieu J. Scintigraphy with J001 macrophage targeting glycopolipeptide A new approach for sarooidosis imaging. Chest 1992; 102: 670–6.PubMedGoogle Scholar
  283. 283.
    Dunn-Dufault R, Pollak A, Thornback JR, Ballinger JR. Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology. Bioconjug Chem 1999; 10: 832–7.PubMedGoogle Scholar
  284. 284.
    Paul C, Peers SH, Woodhouse LE, Thomback J.R, Goodbody AE, Bolton C. The detection and quantitation of inflammation in the central nervous system during experimental allergic encephalomyelitis using the radiopharmaceutical99mTc-RP128. J Neurosci Methods 2000; 98: 83–9.PubMedGoogle Scholar
  285. 285.
    Caveliers V, Goodbody AE, Tran LL, Peers SH, Thornback JR, Bossuyt A. Evaluation of99mTc RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med 2001; 42: 154–61.PubMedGoogle Scholar
  286. 286.
    Moyer BR, Vallabhajosula S, Lister-James J, Bush LR, Cyr JE, Snow DA, Bastidas D, Lipszyc H, Dean RT. Technetium-99i-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection J Nucl Med 1996; 37: 673.PubMedGoogle Scholar
  287. 287.
    Shuang L, Edwards DS.99i’Tc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999; 99: 2235–68.Google Scholar
  288. 288.
    Palestro CJ, Weiland FL, Seabold JE, Valdivia S, Tomas MB, Moyer BR, Baran YM, Lister- James J, Dean RT. Localizing infection with a technetium99in-labeled peptide: initial results. Nucl Med Commun 2001; 22: 695–701.PubMedGoogle Scholar
  289. 289.
    DeNardo GL. When is Too Much Too much and Yet Not Enough? Alas, a Plethora of Opportunities but Where’s the Beef? (comment). J Nucl Med 2000; 41: 470–3.PubMedGoogle Scholar
  290. 290.
    Gomes Barreto V. Marcaje de antibiÓticos con 99mTc para la detecciÓn de focos infecciosos y su diferenciaciÓn de procesos inflamatorios. Doctoral Thesis, University of Barcelona. 2001.Google Scholar
  291. 291.
    Hatice D. Lung clearence of aerosolized 99mT-erythromycin lactobionate in rabits. Nucl Med Biol 1996; 23: 291–3.Google Scholar
  292. 292.
    Diot P. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Resp J 1995; 8: 1263–8.Google Scholar
  293. 293.
    Pinnettis E, Limouris GS, Papadopulous M. Potential infection imaging agents: preparation and biodistribution of99mTc-norFloxacin and99’ Tc-ciprofloxacin. Eur J Nucl Med 1999; 26: 1108.Google Scholar
  294. 294.
    Solanki KK. Tc 99m-Infecton: a new class of radiopharmaceutical for imaging infection. J Nucl Med. 1993; 34: 119P.Google Scholar
  295. 295.
    Hooper DC. Mechanisms of action of and resistance to ciprofloxacin. Am J Med 1987; 82 Suppl 4: 12–20.PubMedGoogle Scholar
  296. 296.
    Hall AV. Evaluation of the efficacy of99mTc - Infecton, a novel agent for detecting sites of infection. J Clin Pathol 1998; 51: 215–9.PubMedCentralPubMedGoogle Scholar
  297. 297.
    Easmon CSF. Effect of ciprofloxacin on intracellular organisms: in vitro and in vivo studies. J Antimicrob Chemother 1986; 18 (suppl D): 43–8.PubMedGoogle Scholar
  298. 298.
    Venjamuri S. Comparison of99mTc Infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection. Lancet 1996; 347: 233–5.Google Scholar
  299. 299.
    Sonmezoglu K. Usefulness of99mTc -Ciprofloxacin (Infecton) scan in diagnosis of chronic orthopedic infections: comparative study with99mTc-HMPAO Leukocyte scintigraphy. J Nucl Med 2001; 42: 567–74.PubMedGoogle Scholar
  300. 300.
    Britton KE.99mTc- “infecton”, preliminary evaluation in over 500 patients through an IAEA coordinated research programme. Eur J Nucl Med 1998; 25: OS 152.Google Scholar
  301. 301.
    Mick M. Technetium-99m labelled antimicrobial peptides and antiinfectives for the detection of bacterial and C.Albicans infections. Eur 1 Nucl Med 2000; EANM 2000, Paris.Google Scholar
  302. 302.
    Debbia E. Activity of Ceftizoxime on Growth, Shape and murein syntesis of PBP Deficient Mutants of Escherichia coli. Proceedings of the 13th International Congress of Chemoterapy. Vienna, Sept 1983.Google Scholar
  303. 303.
    Kwung P. Antibacterial Activity of Ceftizoxime, a B-lactamase-Stable Cephalosporin. Antimicrobial Agents and Chemotherapy, 1980; p.583–590.Google Scholar
  304. 304.
    Gomes Barreto V. Marcaje de ceftizoxima con 99mTc. Rev Esp Med Nucl 2000; 19: 479–483.PubMedGoogle Scholar
  305. 305.
    Wong GWH, Steiner B, Graves S. Effect of four serum components on survival ofTreponema pallidumand its attachment to rabbit cells in vitro. Genitourin Med 1986; 62: 1–3.PubMedCentralPubMedGoogle Scholar
  306. 306.
    Alderete JF, Peterson KM, Baseman JB. Affinities ofTreponema pallidumfor human lactoferrin and transferrin. Genitourin Med 1988; 64: 359–63.PubMedCentralPubMedGoogle Scholar
  307. 307.
    Hackett CJ: Bull Wold Hlth Org 1963; 29: 7.Google Scholar
  308. 308.
    Hudson EH. Non-venereal syphilis. A sociological and medical study of bejel. Edinburgh: Livingstone 1958.Google Scholar
  309. 309.
    Bellotti G, Bocchi EA, Morses AV, Higuchi ML, Barbero Marcial M, Sosa E, Esteves Filho A, Kalil R, Weiss R, Jatene A, Pileggi F. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am Heart J 1996; 131: 301–7.PubMedGoogle Scholar
  310. 310.
    Mortara RA, Silva S, Patricio FR, Higuchi ML, Lopes ER, Gabbai AA, Carnevale P, Rocha A, Ferreira MS, Souza MM, Franco MF, Turcato G Jr, Ferraz-Neto BH. Imaging Trypanosoma cruzi within tissues from chagasic patients using confocal microscopy with monoclonal antibodies. Parasitol Res 1999; 85: 800–8.PubMedGoogle Scholar
  311. 311.
    Gonzalez S, Teran M, Leon Cabana E, Savio E, Leon A, Nieto A. Assessment of the diagnostic value of 99mTc-radiolabelled specific antibodies in experimental hydatidosis. Q J Nucl Med 1996; 40: 161–9.PubMedGoogle Scholar
  312. 312.
    Aikens LM, Schad GA. Radiolabeling of third-stage larvae ofStrongyloides stercoralisby feeding [75Se] Selenomethionine-labeledEscherichia colito first and second stage larvae. J Parasitol 1989; 75: 735–9.PubMedGoogle Scholar
  313. 313.
    Mansfield LS, Alavi A, Wortman JA, Schad GA. Gamma camera scintigraphy for direct visualization of larval migration inStrongyloides stercoralis-infecteddogs. Am J Trop Med Hyg 1995; 52: 236–40.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • V. Cardoso
  • F. J. H. N. Braga

There are no affiliations available

Personalised recommendations